Event is taking place on Thursday, October 6th at 11:30 a.m. ET
Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School)
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.
The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School. During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease. Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.
A live Q&A session will follow the formal presentations. To register for the event, please click here.
